TapImmune Inc. to Present at Invitation Only Corporate Roadshow in Boca Raton Florida

Follow this company

Companies Mentioned

04/24/2014 [ACCESSWIRE]

Seattle WA / ACCESSWIRE / April 24, 2014 / TapImmune Inc. (OTCQB: TPIV), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease is pleased to announce that the company will be presenting at Corporate Road Show.com, in conjunction with, Undiscovered Equities.

The Boca Raton Florida Road Show Event takes place April 29-30, 2014. This two day conference will feature presentations by CEOs and CFOs of promising emerging growth companies. This invitation only event attracts an audience of pre-qualified investment professionals, investment bankers, analysts, portfolio managers, hedge fund managers, top brokers and accredited investors.

TapImmune will be presenting and discussing significant recent company events and outlining 2014 milestones including:

- Progress and interim data in Her2/neu +ve breast cancer and Folate receptor alpha ovarian and breast cancer clinical trials

- Progress in pre-clinical small animal studies in smallpox at Mayo Clinic and license deal and partnering opportunities.

- Major financing

- Uplisting to NASDAQ in 2014

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at http://www.tapimmune.com/ for details.

Forward-Looking Statement Disclaimer:

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.


Glynn Wilson, PH.D.
Chairman & CEO


Source: TapImmune Inc.


Leave a comment...

Your Name